A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

Bristol-Myers Squibb (BMS)

Status: Enrolling

Conditions: Psoriasis

Treatments: Drug: Deucravacitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT06701513

IM011-1127

Details and patient eligibility

About

The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis

Enrollment: 350 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18 years of age
• Physician-reported diagnosis of moderate to severe plaque psoriasis
• Be newly initiating deucravacitinib
• Do not object to participate

Exclusion criteria

• Currently participating in or planning to participate in an interventional clinical trial
• Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial

Trial design

350 participants in 1 patient group

Participants that have initiated deucravacitinib treatment

Treatment:

Drug: Deucravacitinib